drugset
drugset / Trial / NCT04084184

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects

NCT04084184 ↗

Phase 1 Completed 28 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HGP1602 in healthy subjects.

Timeline

Start
2019-03-15
Primary completion
2019-03-25
Completion
2019-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg —

Indications

No indication recorded.